Advanced Micronized Chelation Technology™
A next-generation oral delivery platform for GLP-1 receptor agonists and peptide biologics. AMCT™ replaces gastric disruption with controlled, biologically aligned transport mechanisms.
~200×
Lower API Dose vs. SNAC
180+ days
Sustained Observational Data
0.05–0.35 mg
Observed Daily GLP-1 Range
No fasting
Administration Requirement
5-Stage Delivery Architecture
AMCT™ is a multi-stage delivery architecture engineered to preserve peptide integrity and promote controlled systemic uptake without disrupting normal gastrointestinal physiology. Click each stage to expand the clinical detail.
Oral peptide delivery historically fails due to:
Enzymatic degradation during GI transit
Poor epithelial permeability of large molecules
High variability from gastric physiology
AMCT™ addresses each at the mechanistic root:
Chelation shields from enzymatic degradation
Transcellular transport enables epithelial crossing
Controlled kinetics eliminate gastric variability
Defining Distinction
"The defining distinction of AMCT™ is its alignment with human physiology rather than reliance on transient mucosal injury or gastric manipulation."
— AMCT™ Whitepaper v2.0, Feb 2026
Educational reference only. For licensed prescribers. No claims of bioequivalence or therapeutic equivalence. All prescribing decisions remain with the treating clinician. Confidential — not for patient distribution. Source: AMCT™ Whitepaper Version 2.0, Updated February 2026 · Zoom Biotech / Village Compounding Pharmacy Partnership.